Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?

Liver International

Volumn 30, Issue 10, 2010, Pages 1548-1549

  Chen, Wei Chun ^a   Chen, Wei ^a   Tseng, Guan Chin ^a   Lai, Hsueh Chou ^a   Shih, Chuen Ming ^a   Hsia, Te Chun ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; THYROID TRANSCRIPTION FACTOR 1;

ADULT; ATELECTASIS; BRONCHOSCOPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CASE REPORT; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG COST; ELECTROCOAGULATION; FEMALE; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LIVER CELL CARCINOMA; LIVER FAILURE; LUNG METASTASIS; PROTEIN BLOOD LEVEL; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 78650762234     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02239.x     Document Type: Letter

References (8)

1. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27: 843-50.
2. Giannelli G, Sgarra C, Porcelli L, et al. EGFR and VEGFR as potential target for biological therapies in HCC cells. Cancer Lett 2008; 262: 257-64.
3. Giannelli G, Azzariti A, Fransvea E, et al. Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells. Br J Cancer 2004; 91: 1964-9.
4. Hopfner M, Sutter AP, Huether A, et al. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 2004; 41: 1008-16.
5. Schiffer E, Housset C, Cacheux W, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005; 41: 307-14.
6. Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoel MJ, et al. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 2006; 119: 2557-66.
7. Matsuo M, Sakurai H, Ueno Y, Ohtani O, Saiki I. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib. Cancer Sci 2006; 97: 155-62.
8. Ueda S, Basaki Y, Yoshie M, et al. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer Res 2006; 66: 5346-53.